What Are the Important Risk Factors for Healthcare-Associated Pneumonia?

David S. Poch; David E. Ost

doi:10.1055/s-0028-1119806

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2009; 30(1): 026-035
DOI: 10.1055/s-0028-1119806

What Are the Important Risk Factors for Healthcare-Associated Pneumonia?

David S. Poch¹ , David E. Ost²

¹Department of Pulmonary and Critical Care Medicine, New York University Medical Center, New York, New York
²Department of Pulmonary and Critical Care, Division of Internal Medicine, University of Texas, M.D. Anderson Cancer Center, Houston, Texas

Abstract

ABSTRACT

Healthcare-associated pneumonia (HCAP) is a category of nosocomial pneumonia defined by the 2005 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines to include any patient who has been hospitalized in an acute care hospital for 2 or more days within the past 90 days; residents of a nursing home or long-term care facility; recipients of recent intravenous antibiotic therapy, chemotherapy, or wound care within the past 30 days; or patients who have attended a hospital or hemodialysis clinic. In creating this relatively new category the ATS/IDSA acknowledged that these patients are at increased risk for infection with antibiotic-resistant organisms and that initial inadequate antibiotic coverage leads to increased mortality. Risk factors for the development of pneumonia and the development of pneumonia caused by drug-resistant pathogens, primarily methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, are not the same among the subgroups of HCAP (i.e., dialysis patients have different risks than nursing home patients). Furthermore there is significant heterogeneity of risk factors for HCAP within the subgroups due to variations in contextual factors such as local microbiology and methods of health care delivery and variations of individual risk factors such as functional status or prior antibiotic exposure. This review examines the evidence for the creation of the category of HCAP, including the risk factors for drug-resistant pneumonia in each of the subgroups that constitute HCAP. This review demonstrates that the guidelines have effectively targeted a population at greater risk for pneumonia caused by drug-resistant pathogens. However, within the broad range of HCAP infections, there is significant heterogeneity in terms of the magnitude of the risk as well as the type of risk (i.e., risk for MRSA, multidrug-resistant gram-negative bacilli (MDR-GNB), or both).

KEYWORDS

Healthcare-associated pneumonia - pneumonia - drug-resistant bacteria - Staphylococcus aureus - MRSA - pneumonia epidemiology

Full Text

References

REFERENCES

1 American Thoracic Society; Infectious Diseases Society of America . Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171 388-416
2 Micek S T, Lloyd A E, Ritchie D J et al.. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005; 49 1306-1311
3 Ibrahim E H, Ward S, Sherman G et al.. A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest. 2000; 117 1434-1442
4 Kollef M H. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2000; 31(Suppl 4) S131-S138
5 Luna C M, Vujacich P, Niederman M S et al.. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest. 1997; 111 676-685
6 Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med. 1996; 22 387-394
7 Rello J, Gallego M, Mariscal D et al.. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med. 1997; 156 196-200
8 Kollef M H, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest. 1998; 113 412-420
9 Ibrahim E H, Ward S, Sherman G et al.. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med. 2001; 29 1109-1115
10 Morin C A, Hadler J L. Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998. J Infect Dis. 2001; 184 1029-1034
11 Friedman N D, Kaye K S, Stout J E et al.. Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002; 137 791-797
12 Arancibia F, Bauer T T, Ewig S et al.. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med. 2002; 162 1849-1858
13 Pop-Vicas A E, D'Agata E M. The rising influx of multidrug-resistant gram-negative bacilli into a tertiary care hospital. Clin Infect Dis. 2005; 40 1792-1798
14 Carratala J, Mykietiuk A, Fernandez-Sabe N et al.. Healthcare-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med. 2007; 167 1393-1399
15 Micek S T, Kollef K E, Reichley R M, Roubinian N, Kollef M H. Healthcare-associated pneumonia and community-acquired pneumonia: a single center experience. Antimicrob Agents Chemother. 2007; 51 3568-3573
16 Kollef M H, Shorr A, Tabak Y P et al.. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005; 128 3854-3862
17 Marrie T J, Blanchard W. A comparison of nursing home-acquired pneumonia patients with patients with community-acquired pneumonia and nursing home patients without pneumonia. J Am Geriatr Soc. 1997; 45 50-55
18 Janssens J P, Gauthey L, Herrmann F et al.. Community-acquired pneumonia in older patients. J Am Geriatr Soc. 1996; 44 539-544
19 Muder R R. Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention. Am J Med. 1998; 105 319-330
20 Loeb M B, Craven S, McGeer A J et al.. Risk factors for resistance to antimicrobial agents among nursing home residents. Am J Epidemiol. 2003; 157 40-47
21 El Solh A A, Sikka P, Ramadan F et al.. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med. 2001; 163 645-651
22 El Solh A A, Aquilina A T, Dhillon R S et al.. Impact of invasive strategy on management of antimicrobial treatment failure in institutionalized older people with severe pneumonia. Am J Respir Crit Care Med. 2002; 166 1038-1043
23 Sund-Levander M, Ortqvist A, Grodzinsky E et al.. Morbidity, mortality and clinical presentation of nursing home-acquired pneumonia in a Swedish population. Scand J Infect Dis. 2003; 35 306-310
24 MacArthur R D, Lehman M H, Currie-McCumber C A et al.. The epidemiology of gentamicin-resistant Pseudomonas aeruginosa on an intermediate care unit. Am J Epidemiol. 1988; 128 821-827
25 Wingard E, Shlaes J H, Mortimer E A et al.. Colonization and cross-colonization of nursing home patients with trimethoprim-resistant gram-negative bacilli. Clin Infect Dis. 1993; 16 75-81
26 Washio M, Nishisaka S, Kishikawa K et al.. Incidence of methicillin-resistant Staphylococcus aureus (MRSA) isolation in a skilled nursing home: a third report on the risk factors for the occurrence of MRSA infection in the elderly. J Epidemiol. 1996; 6 69-73
27 Muder R R, Brennen C, Drenning S D et al.. Multiply antibiotic-resistant gram-negative bacilli in a long-term-care facility: a case-control study of patient risk factors and prior antibiotic use. Infect Control Hosp Epidemiol. 1997; 18 809-813
28 Terpenning M S, Bradley S F, Wan J Y et al.. Colonization and infection with antibiotic-resistant bacteria in a long-term care facility. J Am Geriatr Soc. 1994; 42 1062-1069
29 Gaynes R P, Weinstein R A, Chamberlin W et al.. Antibiotic-resistant flora in nursing home patients admitted to the hospital. Arch Intern Med. 1985; 145 1804-1807
30 Trick W E, Weinstein R A, DeMarais P L et al.. Colonization of skilled-care facility residents with antimicrobial-resistant pathogens. J Am Geriatr Soc. 2001; 49 270-276
31 Ewig S, Torres A, El-Ebiary M et al.. Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury: incidence, risk factors, and association with ventilator-associated pneumonia. Am J Respir Crit Care Med. 1999; 159 188-198
32 Lim W S, Macfarlane J T. A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. Eur Respir J. 2001; 18 362-368
33 El Solh A A, Pietrantoni C, Bhat A et al.. Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. Clin Infect Dis. 2004; 39 474-480
34 Yakovlev S V, Stratchounski L S, Woods G L et al.. Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit. Eur J Clin Microbiol Infect Dis. 2006; 25 633-641
35 Maruyama T, Niederman M S, Kobayashi T et al.. A prospective comparison of nursing home-acquired pneumonia with hospital-acquired pneumonia in non-intubated elderly. Respir Med. 2008; 102 1287-1295
36 Slinin Y, Foley R N, Collins A J. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int. 2006; 70 1135-1141
37 Sarnak M J, Jaber B L. Pulmonary infectious mortality among patients with end-stage renal disease. Chest. 2001; 120 1883-1887
38 Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review. J Am Soc Nephrol. 1993; 3 1541-1554
39 Cendoroglo M, Jaber B L, Balakrishnan V S et al.. Neutrophil apoptosis and dysfunction in uremia. J Am Soc Nephrol. 1999; 10 93-100
40 von Baum H, Ober J F, Wendt C et al.. Antibiotic-resistant bloodstream infections in hospitalized patients: specific risk factors in a high-risk population?. Infection. 2005; 33 320-326
41 Glasmacher A, von Lilienfeld-Toal M, Schulte S et al.. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect. 2005; 11(Suppl 5) 17-23
42 Maschmeyer G, Braveny I. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s. Eur J Clin Microbiol Infect Dis. 2000; 19 915-925
43 Freifeld A, Marchigiani D, Walsh T et al.. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 1999; 341 305-311
44 Neuburger S, Maschmeyer G. Update on management of infections in cancer and stem cell transplant patients. Ann Hematol. 2006; 85 345-356
45 Hachem R, Raad I. Prevention and management of long-term catheter related infections in cancer patients. Cancer Invest. 2002; 20 1105-1113
46 Patel P J, Leeper Jr K V, McGowan Jr J E. Epidemiology and microbiology of hospital-acquired pneumonia. Semin Respir Crit Care Med. 2002; 23 415-425
47 Sopena N, Sabria M. Multicenter study of hospital-acquired pneumonia in non-ICU patients. Chest. 2005; 127 213-219
48 Craven D E. What is healthcare-associated pneumonia, and how should it be treated?. Curr Opin Infect Dis. 2006; 19 153-160
49 Cook D J, Walter S D, Cook R J et al.. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med. 1998; 129 433-440
50 Laheij R J, Sturkenboom M C, Hassing R J et al.. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004; 292 1955-1960

David S PochM.D.

Department of Pulmonary and Critical Care Medicine, NYU Medical Center

SKI 9 N, 550 1st Ave., New York, NY 10016

Email: pochd01@med.nyu.edu